Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stomach cancer surgery showdown: which operation saves more lives?

NCT ID NCT07482566

Knowledge-focused Sponsor: Nurettin Şahin Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two surgical procedures for patients with a specific type of cancer where the stomach meets the esophagus. Half of the 120 participants will have only the upper part of the stomach removed (proximal gastrectomy), while the other half will have the entire stomach removed (total gastrectomy). Researchers will track who lives longer without the cancer coming back over three years, and also monitor complications and recovery. The goal is to find out if the less extensive surgery is just as safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If this trial succeeds, it could show that a less extensive surgery (proximal gastrectomy) is as effective as total stomach removal, potentially improving quality of life for patients.
What could go wrong
This is a surgical comparison study, not a test of a new drug or cure. Results may not apply to all patients, and both surgeries carry risks like infection or leakage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Feb 2033

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 90 years * Histologically confirmed locally advanced Siewert type II-III gastroesophageal junction cancer * Considered operable after multidisciplinary tumor board evaluation * Candidate for curative surgical resection with D2 lymphadenectomy * Provision of written informed consent Exclusion Criteria: * Early-stage gastroesophageal junction cancer * Gastric cancers located in the antrum or corpus * Severe anesthetic risk (American Society of Anesthesiologists \[ASA\] class IV or higher) * Pregnancy * Patients unwilling or unable to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Esophageal Neoplasms gastric neoplasm gastroesophageal cancer gastroesophageal junction adenocarcinoma neoplasm of esophagus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophageal neoplasms Gastroesophageal junction cancer Stomach neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bakirkoy Dr. Sadi Konuk Training and Research Hospital

    RECRUITING

    Istanbul, Istanbul, 34147, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.